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Epidermal growth factor has an important role in the
regulation of proliferation and differentiation in epidermal
keratinocytes, as well as in the survival, angiogenesis and
metastasis of cancer cells. Cetuximab is a chimeric monoclo-
nal antibody selective for the epidermal growth factor
receptor that induces a broad range of cellular responses that
enhance tumor sensitivity to radiotherapy and chemother-
apeutic agents. However, it can cause adverse events in the
patient including acneiform eruption, asthenia, abdominal
pain and nausea/vomiting. We report a case of severe
acneiform eruption induced by cetuximab in a 56-year-old
man with colorectal cancer and liver metastases.
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INTRODUCTION
Cetuximab is a chimeric monoclonal antibody
highly selective for the epidermal growth factor
receptor (EGFR), which has demonstrated efficacy
in colorectal, head and neck and non-small-cell
lung cancer. Common adverse events associated
with cetuximab therapy are acneiform eruption,
asthenia, abdominal pain and nausea/ vomiting.
1
Acneiform eruption is the most common adverse
effect with > 60% of incidence and 5.2 - 18% of
grade 3/4 adverse events reported in the clinical
trials.
1-3 Here we report an extensive and severe
acneiform eruption induced by cetuximab.
CASE REPORT
A 56-year-old man was admitted for skin
lesions on the face and upper trunk, which had
developed five days previous. He had previously
undergone therapy with cetuximab (Erbitux ) 250
mg/m
2 weekly (at the first infusion, loading dose
was 400 mg/m
2) and irinotecan (Campto ) 100
mg/m
2 weekly for six consecutive weeks
(followed by two weeks rest) for colorectal cancer
with liver metastases. He did not complain of any
itching or pain. Physical examination revealed
multiple rice-sized erythematous pustules on the
face and upper trunk (Fig. 1). Histopathologic
finding was folliculitis in which periadnexal
neutrophilic infiltrate was prominent (Fig. 2).
Acneiform eruptions were resolved after treat-
ment with oral ciprofloxacin and topical mupirocin
ointment (Bactroban ) for two weeks.
DISCUSSION
EGFR is a transmembrane receptor possessing
tyrosine kinase activity which is stimulated by
growth factors such as epidermal growth factor
(EGF). EGF is crucial for tumor cell proliferation,
inhibition of apoptosis, and other processes
important for cancer progression; including angio-
genesis, invasion and metastasis.
1,2,4 Inhibitors of
EGFR are monoclonal antibodies against EGFR
(e.g. cetuximab, panitumumab) or EGFR tyrosine
kinase inhibitors (e.g. gefitinib, erlotinib).
2
Cetuximab has a higher affinity for EGFR than
EGF and competitively blocks the cellular action
of these naturally occurring ligands.
1 Cetuximab
has also been shown to promote receptor
internalization, thereby down-regulating EGFR.
1,4
Cetuximab is used in many epithelial cancers
that overexpress EGFR, including head and neck,
breast, colon, lung, prostate, kidney, ovarian,
Severe Acneiform Eruption Induced by Cetuximab (Erbitux )
Jung Eun Lee,
1 Sang Ju Lee,
1 Hee Jung Lee,
2 Ju Hee Lee,
2 and Kwang Hoon Lee
2
1Yonsei Star Skin & Laser Clinic,
2Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea.
Received May 22, 2006
Accepted May 1, 2007
Reprint address: requests to Dr. Kwang Hoon Lee, Department
of Dermatology, Yonsei University College of Medicine, 250
Seongsanno, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-2228-
2084, Fax: 82-2-393-9157, E-mail: kwanglee@yuhs.ac
Case ReportJung Eun Lee, et al.
Yonsei Med J Vol. 49, No. 5, 2008
brain, pancreatic, and bladder cancers.
5 Among
these, cetuximab is most commonly prescribed for
metastatic colorectal cancer, administered alone or
in combination with irinotecan-based chemo-
therapy regimens.
1
Skin reactions following cetuximab treatment
are acneiform eruption, xerosis/desquamation,
paronychia, hair changes, telangiectasia and
hyperpigmentation.
2,6,7 Acneiform skin eruption is
the most common adverse event associated with
cetuximab therapy.
1-3,6,7 The resultant rash is pre-
dominantly on the seborrheic areas such as face,
neck, retroauricular area, shoulders, and upper
trunk.
2,6 The skin lesions sometimes consist of
itchy erythematous follicular papules that may
evolve into pustules. The follicular skin lesions are
not preceded by visible comedones and can
therefore not be considered true acne.
2 This
adverse effect is thought to be due to its
interference with the physiological role of EGF in
the epidermis.
1,2,5,7 EGFR is important for auto-
crine regulation of the growth of the epidermis,
cell cycle progression, cell differentiation, cell
movement, and cellular survival.
5
Histopathology is characterized by a superficial
and florid neutrophilic suppurative folliculitis in
which a dense monomorphic infiltrate of neutro-
phils is predominant around the infundibula.
3
Investigation of the follicular toxic effects of
cetuximab is important not only because cetuxi-
mab is a novel antitumor agent that is likely to
gain widespread use, but also because of its in
vivo confirmation of the significant role of EGFR
in follicular homeostasis.
Although acneiform eruption caused by cetuxi-
mab is a relatively common adverse reaction, it
may be worthwhile to pay close attention to this
patient who presented a severe and extensive
eruption.
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Fig. 1. Multiple pinhead to rice-sized erythematous pustules
on the face and upper trunk.
Fig. 2. Neutrophilic iinfiltrate around adnexa in the dermis.